A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
Cureus|2023|Dutta P et al.|18 citations
Tirzepatide is a promising drug with dual-acting glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor activation that has revolutionized the treatment of type 2 diabetes mellitus (T2DM) as an adjunct to diet…
Review
PMID: 37265914
Journal of clinical and experimental hepatology|2023|Kumar A
PMID: 37250871
Diabetes, obesity & metabolism|2023|Kanbay M et al.|34 citations
AIM: To perform a meta-analysis to quantify the effect of tirzepatide on blood pressure and lipids. METHODS: PubMed, Ovid/Medline, Web of Science, Scopus, Cochrane Library and CINAHL databases were screened and the randomized controlled trials evalua…
Meta-Analysis
PMID: 37700437
Cureus|2023|Ahmad B et al.|2 citations
Cardiovascular disease is a major comorbidity associated with diabetes mellitus. Various antidiabetic drugs are currently used to treat type 2 diabetes mellitus and have varying effects on the cardiovascular system. Some drugs, such as glucagon-like…
Review
PMID: 37920618
Current medicinal chemistry|2023|Polyzos S, Goulas A, Papaioannidou P|7 citations
PMID: 36617715
Internal medicine journal|2023|Stretton B et al.|20 citations
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) reduce elevated blood glucose levels and induce weight loss. Multiple GLP-1 RAs and one combined GLP-1/glucose-dependent insulinotropic polypeptide agonist are currently available. This review was…
ReviewMeta-Analysis
PMID: 37189293
Lancet (London, England)|2023|Garvey W et al.|517 citations
BACKGROUND: Weight reduction is essential for improving health outcomes in people with obesity and type 2 diabetes. We assessed the efficacy and safety of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 recepto…
Randomized Controlled Trial
PMID: 37385275
Diabetes, metabolic syndrome and obesity : targets and therapy|2023|Telci Caklili O et al.|24 citations
Obesity has become an epidemic and a worldwide problem and its treatment is ever-evolving. Apart from diet and exercise, medication and surgery are other options. After disappointing side effects of various obesity drugs, new treatments showed promis…
Review
PMID: 37337548
American journal of therapeutics|2023|Wong E et al.|6 citations
BACKGROUND: Diabetes is a chronic disease that can lead to many complications, and controlling glucose balance is essential. Incretin hormones are produced in the gut and are essential to maintaining glucose homeostasis. Their effects range from incr…
Review
PMID: 36516422
Australian prescriber|2023|Unknown authors|1 citation
Review
PMID: 38152319
Diabetes care|2023|Heerspink H et al.|36 citations
OBJECTIVE: Tirzepatide reduces HbA1c and body weight, and creatinine-based estimated glomerular filtration rate (eGFR) decline. Unlike creatine-derived eGFR (eGFR-creatinine), cystatin C-derived eGFR (eGFR-cystatin C) is unaffected by muscle mass cha…
PMID: 37267479
Pharmaceuticals (Basel, Switzerland)|2023|Al Musaimi O et al.|41 citations
A total of 37 new drug entities were approved in 2022; although that year registered the lowest number of drug approvals since 2016, the TIDES class consolidated its presence with a total of five authorizations (four peptides and one oligonucleotide)…
PMID: 36986436
Cureus|2023|Aleman Espino A et al.|6 citations
Acute kidney injury (AKI) involves a rapid decline in kidney function, classified into prerenal, intrarenal, and postrenal causes. Drug-induced AKI's complex pathophysiology includes altered hemodynamics, inflammation, crystal deposition, hemolysis,…
Case Report
PMID: 37720126
Journal of diabetes research|2023|Ma Z et al.|17 citations
Type 2 diabetes mellitus (T2DM) is a chronic progressive metabolic disease that has become a growing health problem worldwide, and the dangers of hyperglycemia and its chronic complications have long been considered a goal of diabetes treatment. In r…
Review
PMID: 37096236
Cureus|2023|Khan Z et al.|2 citations
Our study assessed the efficacy and safety of the three primary tirzepatide (TZP) doses, 5 mg, 10 mg, and 15 mg using network meta-analysis to assess their relative impact on type 2 diabetes mellitus (T2DM) treatment. This study adhered to the Prefer…
Review
PMID: 37779743
JPMA. The Journal of the Pakistan Medical Association|2023|Habiba U, Iqbal A, Kumar S
PMID: 36932808
World journal of clinical cases|2023|Ochani R et al.|11 citations
Fasting during the month of Ramadan is one of the five fundamental principles of Islam, and it is obligatory for healthy Muslim adults and adolescents. During the fasting month, Muslims usually have two meals a day, suhur (before dawn) and iftar (aft…
Review
PMID: 37731557
Cureus|2023|Sharma P, Chakole S|1 citation
Diabetes was considered manageable but not curable, but now there are methods by which diabetes can be reversed. The twin cycle hypothesis provides a bird's eye view on the pathogenesis of the onset of diabetes, which is necessary to understand for r…
Review
PMID: 38094528
Metabolism open|2023|Mima A et al.|32 citations
BACKGROUND: This meta-analysis was conducted to investigate the effects of incretin-based therapeutic agents, including the latest agent tirzepatide, on renal outcomes in patients with type 2 diabetes. METHODS: MEDLINE (via PubMed) and Cochrane datab…
PMID: 36923991
Nutrition, metabolism, and cardiovascular diseases : NMCD|2023|Gómez Lumbreras A et al.|26 citations
BACKGROUND AND AIMS: To determine the cost-effectiveness of anti-obesity medications (AOM): tirzepatide, semaglutide, liraglutide, phentermine plus topiramate (PpT), and naltrexone plus bupropion (NpB). METHODS AND RESULTS: From a U.S. perspective we…
PMID: 37088648